Baudax Bio to Present at the NobleCon Pain Management Investor Forum
MALVERN, Pa., Oct. 5, 2021 – Baudax Bio (NASDAQ:BXRX) announced a corporate presentation at the NobleCon Pain Management Investor Forum on October 7, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
MALVERN, Pa., Oct. 5, 2021 – Baudax Bio (NASDAQ:BXRX) announced a corporate presentation at the NobleCon Pain Management Investor Forum on October 7, 2021. The presentation will be available for registered attendees starting at 11:00 a.m. Eastern Time and can be accessed on Baudax's investor website. Baudax Bio focuses on innovative products for acute care settings, including ANJESO, a 24-hour intravenous NSAID for managing moderate to severe pain, along with a pipeline of neuromuscular blocking agents and a proprietary reversal agent.
Details
News Market Reaction – BXRX
The recorded move for BXRX in the trading session of this news was -1.82%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MALVERN, Pa., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today announced that management will give a corporate presentation followed by a question and answer session at the NobleCon Pain Management Investor Forum being held virtually on Thursday, October 7, 2021.
The presentation will be made available to registered attendees (cost free) for on-demand listening beginning Thursday, October 7, 2021 at 11:00 a.m. Eastern Time and may be accessed on the “Events” page within the investors section of the Baudax Bio website at https://www.baudaxbio.com/news-and-investors. The recording will be archived as part of its C-Suite Series at https://www.channelchek.com/c-suite.
About Baudax Bio
Baudax Bio is a pharmaceutical company focused on commercializing and developing innovative products for acute care settings. ANJESO is the first and only 24-hour, intravenous (IV) COX-2 preferential non-steroidal anti-inflammatory (NSAID) for the management of moderate to severe pain. In addition to ANJESO, Baudax Bio has a pipeline of other innovative pharmaceutical assets including two novel neuromuscular blocking agents (NMBAs) and a proprietary chemical reversal agent specific to these NMBAs. For more information, please visit www.baudaxbio.com.
CONTACTS:
Investor Relations Contact:
Argot Partners
Sam Martin / Claudia Styslinger
(212) 600-1902
baudaxbio@argotpartners.com
Media Contact:
Argot Partners
David Rosen
(212) 600-1902
david.rosen@argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.